Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.51 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.51 |
| ▸ | PAM | P19021 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6193432 | 1.00 | HTR2A (0.54) | HTR2AGRIK1GRIK2PAMADAM17 | |
| SCHEMBL4290351 | 1.00 | HTR2A (0.54) | HTR2AGRIK1GRIK2PAMADAM17 | |
| SCHEMBL6193437 | 1.00 | HTR2A (0.54) | HTR2AGRIK1GRIK2PAMADAM17 | |
| SCHEMBL3252073 | 0.88 | HTR2A (0.56) | HTR2AGRIK1GRIK2PAMADAM17 | |
| SCHEMBL3252075 | 0.88 | HTR2A (0.56) | HTR2AGRIK1GRIK2PAMADAM17 | |
| SCHEMBL16156177 | 0.84 | HTR2A (0.49) | HTR2AGRIK1GRIK2PAMADAM17 | |
| SCHEMBL16147764 | 0.84 | HTR2A (0.49) | HTR2AGRIK1GRIK2PAMADAM17 | |
| SCHEMBL17510950 | 0.84 | HTR2A (0.49) | HTR2AGRIK1GRIK2PAMADAM17 | |
| SCHEMBL6188858 | 0.84 | HTR2A (0.49) | HTR2AGRIK1GRIK2PAMADAM17 | |
| SCHEMBL17510949 | 0.84 | HTR2A (0.49) | HTR2AGRIK1GRIK2PAMADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
| EP-1984500-A2 | ADAM10 AND ITS USES RELATED TO INFECTION | VANDERBILT UNIVERSITY (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007084488-A2 | ADAM10 AND ITS USES RELATED TO INFECTION | VANDERBILT UNIVERSITY (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1121118-A4 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LTD (GB) | 2002-09-11 | — | — | EP | disclosed |
| US-6329400-B1 | INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS | GLAXO WELLCOME INC. | 2001-12-11 | — | — | US | disclosed |
| EP-1121118-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2001-08-08 | — | — | EP | disclosed |
| US-6172064-B1 | METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-01-09 | — | — | US | disclosed |
| WO-2000012083-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | HTR2A 4843/4885GRIK1 2530/4885GRIK2 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.